Europe Unlicensed Specials Prescribing Settings and Distribution Channels

Why Setting and Channel Are Analysed Together

A special is prescribed in a setting and delivered through a channel, and the two together determine how a supplier reaches the buyer. In the Europe unlicensed specials market the prescription setting dimension has four categories and the distribution channel dimension has six.

Prescription setting asks where the clinical decision is made: hospital prescribing, community prescribing, specialist clinics or homecare. Distribution channel asks how the product physically and commercially travels: hospital pharmacy, community pharmacy, NHS procurement, wholesalers, specialty distributors or direct manufacturer supply.

The two are not one-to-one. A hospital prescriber may be supplied through the hospital pharmacy, through NHS procurement agreements or by a wholesaler, and a specialist clinic may be supplied directly by a manufacturer. The report keeps them separate to show where suppliers can add value at each step.

For suppliers the practical consequence is that the same product may need different commercial models in different settings: a framework agreement and delivery schedule for a hospital, a wholesale listing for community pharmacy and a courier service for homecare.

The channel descriptions below are category-level and do not describe the terms, volumes or prices of any contract.

Understanding the combination early also protects against a common error, which is to assume that a hospital customer will always buy through the hospital pharmacy. In practice the hospital pharmacy is the point of contact but the actual purchase may flow through a framework, a hub or a wholesaler, and the supplier must be positioned in each.

The report treats these as complementary lenses so that a reader can ask two separate questions: who decides to prescribe a special, and who decides to buy it.

Hospital and Community Prescribing

Hospital prescribing is the largest setting for unlicensed specials. Hospitals treat patients with the most complex needs, including pediatric inpatients, oncology patients and those with swallowing difficulty, and clinical teams frequently need products that no licensed range provides.

Hospital demand is shaped by the formulary, by the hospital's own preparation capability and by the speed at which a ward needs a product. The demand is steady for oral liquids and more urgent for sterile products. NHS trusts, public hospitals and private hospitals are separate customer segments in the report, each with its own purchasing pattern.

Community prescribing covers general practice and other primary care prescribers whose prescriptions are dispensed by community pharmacies. Volumes per prescription are smaller and the supplier is typically a wholesaler or a manufacturer working through wholesalers, rather than a direct contractual relationship with the prescriber.

The difference in supply model has consequences for products. Hospital buyers may accept a longer lead time for a planned product, while community prescriptions need to be filled within the patient's expected timescale, which favours suppliers with stock held close to the pharmacy.

Taken together the two settings explain why both direct supply and wholesale distribution coexist, and why a supplier's ability to serve both is regarded in the report as part of its distribution capability.

Hospitals with their own aseptic or manufacturing units occupy a particular position, because they supply some of their own needs and only buy externally when volume, capability or timing require it. External suppliers therefore compete partly with the hospital itself, and hospital outsourcing is a recurring area of opportunity in the competitive chapters.

Specialist Clinics and Homecare

Specialist clinics and homecare are smaller settings that matter disproportionately to special-order demand. Specialist treatment centres, oncology centres, pediatric hospitals and rehabilitation hospitals are named healthcare customer segments in the report, and each concentrates patients with specific formulation needs.

Specialist clinics typically work with a small number of regular suppliers and value clinical support, technical information and responsiveness. They may also be the first to request a new formulation, which gives suppliers an opportunity to develop products that later reach a wider market.

Homecare is a growing setting, driven by policies and patient preferences that move treatment out of hospital. Homecare pharmacies are a distinct pharmacy segment in the report. The products are often oral liquids and other presentations to be used by patients or carers, and delivery to the home is part of the service.

The commercial features of homecare are different from hospital supply. Order sizes are individual, delivery needs to be reliable and scheduled, and communication with carers matters as much as communication with prescribers. Suppliers that provide this service model hold a position that product capability alone does not give.

Both settings link to the faster delivery models identified as an opportunity in the competitive chapters, since the patient is at home or in a clinic awaiting the product and delays are felt directly.

Rehabilitation hospitals and long-term care environments are often overlooked, yet they combine many of the patient groups with the highest special demand, notably elderly and dysphagia patients, and they may be supplied through a mix of hospital pharmacy and homecare pharmacy models.

Medical devices and administration aids, such as oral syringes and measuring cups, are commonly supplied with homecare products, and suppliers that include these items as part of the order remove a practical barrier for carers.

Hospital Pharmacy, Community Pharmacy and NHS Procurement

Hospital pharmacy is the principal channel for hospital-prescribed specials. Chief pharmacists and hospital pharmacy directors manage the formulary, decide which products are purchased and sometimes prepare products themselves, and the pharmacy is therefore both a customer and, in part, a competitor to external suppliers.

Community pharmacy covers pharmacy chains and independent pharmacies. Chains such as those named in the stakeholder coverage of the report purchase at scale through central teams, while independents buy through wholesalers and pharmacy purchasing groups. Specialist pharmacy providers and homecare pharmacies form further distinct groups.

NHS procurement is a channel in its own right in the United Kingdom, covering framework agreements and national and regional purchasing. The structure of these agreements, which are part of the broader manufacturing and import routes that bring products to buyers, concentrates volume with approved suppliers and sets the conditions under which products are supplied.

Contract value bands in the full report distinguish small hospital contracts, regional framework contracts and national procurement agreements. Each band involves a different decision maker, from a single chief pharmacist to a national procurement body.

The channel mix differs by country. Outside the United Kingdom, hospital buying is generally more decentralised, so more suppliers deal with individual hospitals or regional groups and the role of national frameworks is smaller.

Pharmacy purchasing groups and regional procurement hubs act as aggregators, and a supplier that wins a place with one of them gains access to a large number of independent pharmacies and smaller hospitals at once, with a single negotiation and a more predictable volume.

Hospital pharmacy chief pharmacists often act as gatekeepers for formulary entry, so a product's presence on a procurement framework does not by itself guarantee use, and suppliers combine framework positioning with direct engagement of pharmacy teams.

Wholesalers, Specialty Distributors and Direct Supply

Wholesalers are the broadest route to community pharmacy and a major route to hospitals. Large wholesaling groups hold extensive catalogues, run frequent deliveries and provide the credit and logistics that small pharmacies rely on. Several of the companies in the full report operate in this part of the chain.

Specialty distributors focus on categories that need particular handling or expertise, such as imported unlicensed medicines, cold-chain products and named patient supply. They offer sourcing, documentation and rapid delivery rather than a large catalogue, and they are a key channel for products that wholesalers do not stock.

Direct manufacturer supply bypasses intermediaries. A manufacturer delivers straight to a hospital pharmacy or specialist centre, usually under a contract or framework. This gives the manufacturer more control over service and a closer relationship with the clinical team, at the cost of carrying the logistics and credit itself.

The balance between the three depends on the product. High-volume oral liquids with broad demand often move through wholesalers, low-volume imports through specialty distributors, and made-to-order products, sterile preparations in particular, through direct supply.

For a supplier, choosing channels is therefore a strategic decision about cost, control and reach, and an overview of the manufacturers and distributors involved shows how companies of different types have made different choices.

Another factor in channel choice is the handling that a product needs. Cold-chain items, short-shelf-life sterile products and controlled documentation for imports all narrow the field of channels that can serve them reliably, and a supplier must match its chosen channel to the product's handling profile.

Geographic coverage matters here, because a wholesaler or distributor with national depot networks can offer next-day delivery that a smaller supplier cannot, which is one reason why geographic coverage and distribution capability appear as separate benchmarking measures in the full report.

Procurement Models and Decision Makers

Procurement models in the full report are NHS framework agreements, direct purchasing, regional procurement hubs and pharmacy purchasing groups. Framework agreements set the terms under which approved suppliers may be called on, direct purchasing allows a buyer to place orders as needed, and hubs and purchasing groups pool the demand of several buyers.

Decision makers include chief pharmacists, hospital pharmacy directors, medicines procurement managers, clinical directors and pharmacy purchasing committees. The balance of influence varies with the type of purchase: a routine oral liquid reorder is a pharmacy decision, while a new sterile product may require clinical director and committee approval.

Buying behaviours in the report include medicine shortage response, named patient prescribing, therapeutic substitution, procurement urgency and the clinical approval process. Shortage response and urgency favour suppliers with stock and fast delivery, and clinical approval favours those with clear documentation and clinical support.

Vendor selection criteria in the report include regulatory compliance, manufacturing quality, delivery reliability, product availability, formulation capabilities, stability studies, pricing and clinical support. Pricing is one criterion among eight, and the others suggest that service and capability are as important as cost.

For commercial teams the best way to use this information is to map each target customer by setting, channel, procurement model and decision maker before approaching it, and to build the offer accordingly, instead of presenting a single catalogue to every buyer.

These models also change over time. Consolidation of hospital buying into hubs, and the growing use of digital ordering, are altering which decision maker is involved in each purchase, so that supplier engagement strategies need to be revisited as procurement evolves.

Clinical directors and pharmacy purchasing committees tend to be involved where a product carries higher clinical significance or where the cost to the institution is greater, and suppliers prepare different materials for each audience.